Steve Krognes Net Worth

The estimated Net Worth of Steve E. Krognes is at least $16.3 Million dollars as of 31 August 2024. Mr. Krognes owns over 155 units of Denali Therapeutics Inc stock worth over $260,049 and over the last 9 years he sold DNLI stock worth over $13,535,921. In addition, he makes $2,530,680 as Chief Financial Officer and Treasurer at Denali Therapeutics Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Mr. Krognes DNLI stock SEC Form 4 insiders trading

Steve has made over 39 trades of the Denali Therapeutics Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 155 units of DNLI stock worth $4,197 on 31 August 2024.

The largest trade he's ever made was selling 92,500 units of Denali Therapeutics Inc stock on 1 April 2024 worth over $1,896,250. On average, Steve trades about 6,117 units every 29 days since 2016. As of 31 August 2024 he still owns at least 9,603 units of Denali Therapeutics Inc stock.

You can see the complete history of Mr. Krognes stock trades at the bottom of the page.

Steve Krognes biography

Steve E. Krognes serves as Chief Financial Officer, Treasurer of the Company. Mr. Krognes joined Denali from Genentech, where he served as Chief Financial Officer and a member of the Executive Committee from April 2009 to September 2015. Mr. Krognes also oversaw Genentech’s Site Services organization between 2011 and 2015, and Genentech’s IT organization between 2009 and 2011. He chaired the Genentech Access to Care Foundation between 2009 and 2015. From January 2004 to April 2009, Mr. Krognes served as Head of Mergers & Acquisitions and a member of the Finance Executive Committee at Roche, a Swiss biotechnology company. From July 2002 to December 2003, Mr. Krognes served as Director of M&A at Danske Bank based in Norway. Mr. Krognes currently serves as a member of the boards of directors of Corvus Pharmaceuticals, a biopharmaceutical company, RLS Global, a Swedish life science company, and Gritstone Oncology, a biotechnology company. Mr. Krognes served as a board member of the California Life Science Association between 2010 and 2015 and California Academy of Sciences from 2014 to 2018. He received his M.B.A. from Harvard Business School and his B.S. in Economics from The Wharton School of the University of Pennsylvania.

What is the salary of Steve Krognes?

As the Chief Financial Officer and Treasurer of Denali Therapeutics Inc, the total compensation of Steve Krognes at Denali Therapeutics Inc is $2,530,680. There are 1 executives at Denali Therapeutics Inc getting paid more, with Ryan Watts having the highest compensation of $4,978,610.

How old is Steve Krognes?

Steve Krognes is 51, he's been the Chief Financial Officer and Treasurer of Denali Therapeutics Inc since 2015. There are 11 older and 8 younger executives at Denali Therapeutics Inc. The oldest executive at Denali Therapeutics Inc is Vicki Sato, 71, who is the Independent Chairman of the Board.

What's Steve Krognes's mailing address?

Steve's mailing address filed with the SEC is 3100, Hanover Street, Palo Alto, Santa Clara County, California, 94306, United States.

Insiders trading at Denali Therapeutics Inc

Over the last 7 years, insiders at Denali Therapeutics Inc have traded over $438,930,443 worth of Denali Therapeutics Inc stock and bought 275,000 units worth $4,950,000 . The most active insiders traders include Llc Fmr, Douglas Kakdl, L.P.Crestlin..., and Jay T Flatley. On average, Denali Therapeutics Inc executives and independent directors trade stock every 11 days with the average trade being worth of $1,606,006. The most recent stock trade was executed by Vicki L Sato on 3 September 2024, trading 3,080 units of DNLI stock currently worth $77,000.

What does Denali Therapeutics Inc do?

denali therapeutics inc. (“denali”) is a biotechnology company focused on the discovery and development of therapies for patients with neurodegenerative diseases, including alzheimer’s disease, parkinson’s disease, als and others. denali was founded by scientists, industry experts and investors who share the vision that recent scientific insights into the genetic causes and biological processes underlying neurodegenerative disease, together with new translational medicine tools, offer an unprecedented opportunity to discover and develop effective medicines. denali is rigorously pursuing a science-driven approach to translational medicine and clinical development. founding investors include fidelity biosciences, arch venture partners, flagship ventures and the alaska permanent fund (represented by crestline investors).

Complete history of Mr. Krognes stock trades at Corvus Pharmaceuticals Inc, Denali Therapeutics Inc, Gritstone Bio Inc, Guardant Health Inc, and Pliant Therapeutics

Denali Therapeutics Inc executives and stock owners

Denali Therapeutics Inc executives and other stock owners filed with the SEC include:

• Ryan Watts,
  President, Chief Executive Officer, Co-Founder, Director
• Steve Krognes,
  Chief Financial Officer, Treasurer
• Carole Ho,
  Chief Medical Officer, Head of Development
• Alexander Schuth,
  Co-Founder, Chief Operating Officer, Secretary
• Dr. Ryan J. Watts Ph.D.,
  Co-Founder, Pres, CEO & Director
• Steve Edward Krognes,
  CFO & Treasurer
• Dr. Carole Ho,
  Chief Medical Officer & Head of Devel.
• Dr. Alexander O. Schuth M.D.,
  Co-Founder, COO & Sec.
• Dr. Carole Ho M.D.,
  Chief Medical Officer & Head of Devel.
• Vicki Sato,
  Independent Chairman of the Board
• Marc Tessier-Lavignec,
  Independent Director
• Peter Klein,
  Independent Director
• David Schenkein,
  Independent Director
• Jay Flatley,
  Independent Director
• Douglas Cole,
  Independent Director
• Robert Nelsen,
  Independent Director
• Jennifer Cook,
  Independent Director
• Dr. Marc Tessier-Lavigne Ph.D.,
  Co-Founder, Chairman of Scientific Advisory Board & Independent Director
• Dr. Marc Tessier-Lavigne,
  Co-Founder, Chairman of Scientific Advisory Board & Independent Director
• Chris Walsh,
  Associate Gen. Counsel
• Dr. Laura Hansen,
  VP of Investor Relations
• Joe Lewcock,
  Chief Scientific Officer
• Dr. Dana Andersen,
  Chief Technical and Manufacturing Officer
• Tyler M. Nielsen,
  VP of Corp. Fin.
• Douglas Kakdl, L.P.Neuro Li...,
  
• Ventures Fund V, L.P.Afeyan...,
  
• Marc Tessier Lavigne,
  Director
• Ltd Fil,
  
• Llc Fmr,
  
• Venture Fund Viii, L.P.Arch...,
  
• Douglas K Neuro Line Partne...,
  
• Douglas Kakdl, L.P.Crestlin...,
  
• Nancy Thornberry,
  Director
• Erik Harris,
  Director